subscribeSubscribe
Heron Therapeutics Announces Partnership with CrossLink Life Sciences

Heron Therapeutics Announces Partnership with CrossLink Life Sciences
PR NEWSWIRE
07 Jan 2024
Share Share
Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF

Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF
PR NEWSWIRE
29 Dec 2022
Share Share
Innocoll and DURECT Announce U.S. launch of POSIMIR®

Innocoll and DURECT Announce U.S. launch of POSIMIR®
PRNEWSWIRE
26 Sep 2022
Share Share
Enforcement Report - Week of August 24, 2022

Enforcement Report - Week of August 24, 2022
FDA
24 Aug 2022
Share Share
FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.

FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.
FDA
13 Jun 2022
Share Share
FDA Confirms Paragraph IV Patent Litigation for Bupivacaine Liposome

FDA Confirms Paragraph IV Patent Litigation for Bupivacaine Liposome
FDA
13 Jun 2022
Share Share
Pacira Biosciences Reports Preliminary Revenues Of $158.4M for Q1 2022

Pacira Biosciences Reports Preliminary Revenues Of $158.4M for Q1 2022
PRESS RELEASE
12 Apr 2022
Share Share
FDA approves expansion for ZYNRELEF

FDA approves expansion for ZYNRELEF
PHARMAFILE
10 Dec 2021
Share Share
Heron Announces FDA Approval of Significant Indication Expansion for ZYNRELEF

Heron Announces FDA Approval of Significant Indication Expansion for ZYNRELEF
PRNEWSWIRE
09 Dec 2021
Share Share
Pacira buys Flexion for $450M to boost pain offerings

Pacira buys Flexion for $450M to boost pain offerings
Angus Liu FIERCEPHARMA
12 Oct 2021
Share Share